Home Stem Cells & Wnt Hedgehog/Smoothened antagonist PF-5274857 For research use only.

PF-5274857

PF-5274857 is a potent and selective Smoothened (Smo) antagonist, inhibits Hedgehog (Hh) signaling with IC50 and Ki of 5.8 nM and 4.6 nM, respectively, and can penetrate the blood–brain barrier.

PF-5274857 Chemical Structure

PF-5274857 Chemical Structure

CAS No. 1373615-35-0

Purity & Quality Control

PF-5274857 Related Products

Signaling Pathway

Hedgehog/Smoothened Signaling Pathways

Hedgehog/Smoothened Signaling Pathway

Biological Activity

Description PF-5274857 is a potent and selective Smoothened (Smo) antagonist, inhibits Hedgehog (Hh) signaling with IC50 and Ki of 5.8 nM and 4.6 nM, respectively, and can penetrate the blood–brain barrier.
Targets
Smoothened [1] Smoothened [1]
4.6 nM(Ki) 5.8 nM
In vitro
In vitro PF-5274857 completely inhibits Shh-induced Hh pathway activity with IC50 of 2.7 nM measured by the transcriptional activity of Smo downstream gene Gli1 in MEF cells. The μ-opioid receptor is weakly inhibited by PF-5274857 with a dissociation constant of 36 μM subsequently determined in a functional assay. [1]
Kinase Assay Biochemical assays
HEK293 cells overexpressing human Smo (amino acids 181-787) are grown in Dulbecco's Modified Eagle's Media (DMEM) supplemented with 10% FBS, Pen–Strep, and 0.1 mg/mL hygromycin to 90% confluence. After washing with cold Dulbecco's PBS, the cell pellet is resuspended in membrane preparation buffer (50 mM Tris-HCl, pH 7.5, 250 mM sucrose with Roche complete protease cocktail) and homogenized. The homogenate is centrifuged and the cell pellet is resuspended in assay buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 25 mM MgCl2, 1 mM EDTA, and 0.1% protease-free bovine serum albumin) and homogenized in a glass tissue grinder. Total protein in the membrane preparation containing Smo is determined using the Pierce BCA protein assay. For the competitive binding assay, 100 μL of assay buffer is added to a 96-well GF/B filter plate for 10 minutes to pre-wet the filter and then removed. The following reagents are then added: 20 μL of assay buffer, 10 μL serial dilutions of compound, 20 μL of 3H-Smo antagonist (3 nM final concentration), and 50 μL of membrane preparation (40 μg total protein). The plates are incubated at room temperature for 2 hours, then washed and vacuum dried. The plates are then dried for 1 hour in a 60°C oven before the addition of 45 μL of Microscint 20 and incubated at room temperature for 30 minutes to 1 hour, then counted in a TopCount scintillation counter. The data are analyzed using GraphPad Prism software.
Cell Research Cell lines Gli-Luc/MEF cells
Concentrations 50 pM- 3 μM
Incubation Time 48 hours
Method Gli-Luc/MEF cells are grown in the knockout DMEM supplemented with 10% heat-inactive FBS, 2 mM l-glutamine, and 0.55 mM β-mercaptoethanol until 90% confluence. On day 1, cells are trypsinized and seeded into white 384-well plates in 20 μL per well of OptiMEM media that is supplemented with 1% heat-inactive FBS and 1 mM sodium pyruvate at a concentration of 7,500 cells per well. Plates are incubated at 37 °C and 5% CO2 overnight. On day 2, PF-5274857 is added to the cells at a final concentration ranging from 3 μM to 50 pM at a 3-fold serial dilution followed by addition of recombinant mouse Sonic Hedgehog to a final concentration of 2 μg/mL. The cells are incubated with PF-5274857 and Shh for 48 hours at 37 °C and 5% CO2. Luciferase assays are conducted on day 4 using the Bright-Glo Luciferase Assay System. Briefly, Bright-Glo luciferase reagent (25 μL) is added to each well of the 384-well plate containing media. Plates are kept at room temperature for 5 minutes and then read on a Luminescence plate reader. The IC50 value of PF-5274857 is calculated.
In Vivo
In vivo PF-5274857 shows significant dose-dependent tumor growth inhibition (TGI) and induces tumor regression at high doses(>10 mg/kg)., PF-5274857 downregulates Gli1, Gli2, Ptch1, and Ptch2 gene expression levels to various degrees with maximal effects being achieved between 6 and 12 hours post-dose (Gli1 is the most sensitive gene), whereas PF-5274857 has little effect on Smo levels. In skin tissue, downregulation of Gli1 and Gli2 is also observed with a similar time course by PF-5274857. The model-derived drug concentration for half maximal inhibition of the tumor Gli1 mRNA production rate (IC50) by PF-5274857 is determined to be 8.9 nM in the Ptch+/−p53+/− medulloblastoma allograft mice, which mathematically corresponds to tumor regression of 119% TGI after 6 days of plasma exposure at this concentration. In the Ptch+/−p53−/− medulloblastoma allograft mice, the IC50 value is estimated to be 3.5 nM, consistent with the Ptch+/−p53+/− results. PF-5274857 is also able to cross the blood–brain barrier in rats within 4 hours post-dose. [1]
Animal Research Animal Models SCID-beige mice bearing primary Ptch+/−p53+/− or Ptch+/−p53−/− medulloblastoma tumor
Dosages ~30 mg/kg
Administration Oral administration

Chemical Information & Solubility

Molecular Weight 436.96 Formula

C20H25ClN4O3S
CAS No. 1373615-35-0 SDF Download PF-5274857 SDF
Smiles CC1=CC(=C(N=C1)C2=CC(=NC=C2Cl)N3CCN(CC3)C(=O)CCS(=O)(=O)C)C
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 93 mg/mL ( (212.83 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 93 mg/mL

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy PF-5274857 | PF-5274857 supplier | purchase PF-5274857 | PF-5274857 cost | PF-5274857 manufacturer | order PF-5274857 | PF-5274857 distributor